Section Arrow
FTRE.NASDAQ
- Fortrea Holdings
Quotes are at least 15-min delayed:2024/10/31 18:36 EDT
Last
 16.82
-0.33 (-1.92%)
Day High 
17.06 
Prev. Close
17.15 
1-M High
20.1 
Volume 
1.01M 
Bid
16.49
Ask
17.23
Day Low
16.53 
Open
16.96 
1-M Low
17 
Market Cap 
1.54B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 18.17 
20-SMA 18.52 
50-SMA 20.29 
52-W High 41.02 
52-W Low 17 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.22/0.06
Enterprise Value
3.17B
Balance Sheet
Book Value Per Share
16.31
Cash Flow
Cash Flow Yield
0.18
Income Statement
Total Revenue
3.11B
Operating Revenue Per Share
34.39
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ELABElevai Labs0.059-0.0339-36.49%-- 
AVTEAerovate Therapeutics2.46+0.27+12.33%-- 
ENSCEnsysce Biosciences0.5754-0.0629-9.85%-- 
TNXPTonix Pharmaceuticals Holding Corp.0.1445-0.0099-6.41%-- 
GLYCGlycoMimetics0.4069-0.0496-10.87%-- 
Quotes are at least 15-min delayed:2024/10/31 18:36 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.